Avance Clinical Brings 30 Years of Early-Phase and Therapeutic Leadership to European Biotechs at BIO-Europe 2026

Why European biotechs start early-phase trials in Australia

Under Australia’s CTN scheme, early-phase studies in Australia can begin once a Human Research Ethics Committee (HREC) approves them. No US Investigational New Drug (IND) application, EU Clinical Trial Application (CTA) or pre-approval from Australia’s Therapeutic Goods Administration (TGA). Ethics approval typically takes 5–6 weeks. Avance Clinical generates ICH-GCP-compliant data to support regulatory submissions to global regulators including the FDA, EMA, MHRA and TGA.

Eligible companies can also access the Australian Government’s R&D Tax Incentive. It provides a refundable tax offset of up to 43.5% on eligible R&D expenditure, including clinical trial costs, for eligible companies.

Global from day one

Through its GlobalReady model, Avance Clinical plans programs for multi-regional expansion from the outset. Sponsors get 480+ specialists across Australia, New Zealand, Asia Pacific, North America and Europe, and access to 2,000+ specialised partnered clinical sites. A single electronic data capture (EDC) system, clinical trial management system (CTMS), electronic trial master file (eTMF) and safety database give sponsors one view of their programme from day one.